{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:11:14Z","timestamp":1791202274606,"version":"4.2.0"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T00:00:00Z","timestamp":1316044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"The National Cancer Institute","doi-asserted-by":"crossref","award":["NO1-CM-42216"],"award-info":[{"award-number":["NO1-CM-42216"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"The National Cancer Institute","doi-asserted-by":"crossref","award":["CA21765"],"award-info":[{"award-number":["CA21765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"The National Cancer Institute","doi-asserted-by":"crossref","award":["CA108786"],"award-info":[{"award-number":["CA108786"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>JNJ\u201026854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ\u201026854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC<jats:sub>50<\/jats:sub> (0.85\u2009\u00b5M) than the remaining cell lines. In vivo JNJ\u201026854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild\u2010type p53. Pediatr Blood Cancer 2012;59:329\u2013332. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/pbc.23319","type":"journal-article","created":{"date-parts":[[2011,9,15]],"date-time":"2011-09-15T19:36:17Z","timestamp":1316115377000},"page":"329-332","source":"Crossref","is-referenced-by-count":22,"title":["Initial testing of JNJ\u201026854165 (Serdemetan) by the pediatric preclinical testing program"],"prefix":"10.1002","volume":"59","author":[{"given":"Malcolm A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gorlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Carol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Maris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Keir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Patrick","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min H.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Arts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarig","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Janicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raushan T.","family":"Kurmasheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,15]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"ArtsJ PageM ValckxA et al. JNJ\u2010 2685 4165 \u2010 a novel Hdm2 antagonist in clinical development showing broad\u2010spectrum preclinical antitumor activity against solid malignancies.Proceedings of the 99th Annual Meeting of the American Association for Cancer Research2008; Abstr #1592."},{"key":"e_1_2_6_3_2","unstructured":"ArtsJ SmansKA AndriesL et al. Preclinical and clinical pharmacodynamic activity of JNJ\u201026854165: A novel Hdm2 antagonist in clinical development.Proceedings of the 100th Annual Meeting of the American Association for Cancer Research2009; Abstr # 1924."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0337"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0792"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0305"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.11"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2955"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.3.4.801"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1587"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507493103"},{"key":"e_1_2_6_12_2","article-title":"Neoadjuvant MDM2 antagonist RG7112 for well\u2010differentiated and dedifferentiated liposarcomas (WD\/DD LPS): A pharmacodynamic (PD) biomarker study","volume":"29","author":"Ray\u2010Coquard IL","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3039","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112 an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors","volume":"29","author":"Beryozkina A","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_14_2","article-title":"A multi\u2010center, open\u2010label, phase I study of single agent RG7112 a first in class p53\u2010MDM2 antagonist, in patients with relapsed\/refractory acute myeloid and lymphoid leukemias (AML\/ALL) and refractory chronic lymphocytic leukemia\/small cell lymphocytic lymphomas (CLL\/SCLL)","volume":"116","author":"Andreeff M","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0331"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21078"},{"key":"e_1_2_6_17_2","first-page":"4189","article-title":"Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents","volume":"48","author":"Friedman HS","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2911"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.3514","article-title":"Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM\u20102 antagonist JNJ\u201026854165 in patients with advanced refractory solid tumors","volume":"27","author":"Tabernero J","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23319","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.23319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.23319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T13:15:05Z","timestamp":1696770905000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.23319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,15]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1002\/pbc.23319"],"URL":"https:\/\/doi.org\/10.1002\/pbc.23319","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,15]]}}}